Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Djaouida Belkadi"'
Autor:
Hugues Hermann, Séverine Roy, Sandrine Agoussi, Emilie Routier, Céline Boutros, Djaouida Belkadi, Haoliang Xue, Antoine Lainé, Stephan Vagner, Daniel Gautheret, Caroline Robert
Publikováno v:
Cancer Research. 83:4282-4282
Introduction: Predicting response to immune checkpoint inhibitors (ICI) is key for stratifying patients and identifying factors of resistance. The main recognized ICI response biomarkers in melanoma are T-cell gene expression signatures, PD-L1 expres
Autor:
Laura Soumoy, Virginie Quidville, Lisa Fredeau, Giuseppina Claps, Caroline Pradon, Ludovic Lacroix, Emilie Routier, Djaouida Belkadi, Séverine Roy, Feras Chehade, Stephan Vagner, Caroline Robert
Publikováno v:
Cancer Research. 83:2177-2177
Introduction: High LDH activity is associated with a poor prognosis in many cancer types, especially in melanoma where it is the strongest indicator of poor outcome even with the most potent anticancer immunotherapies or targeted therapies. Although
Autor:
Jeremy Lupu, Emilie Routier, Julie Blanc, Anais Vallet, Caroline Robert, Djaouida Belkadi-Sadou
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A192
Autor:
Jeremy Lupu, Anais Vallet, Marine Antigny, Emilie Routier, Djaouida Belkadi, Caroline Robert, Séverine Roy, Amelie Dutheil
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A136
Autor:
Amelie Dutheil, Djaouida Belkadi, Jeremy Lupu, Marine Antigny, Caroline Robert, Séverine Roy, Anais Vallet, Emilie Routier
Publikováno v:
Journal of Clinical Oncology. 39:9550-9550
9550 Background: Since the development of immune checkpoint inhibitors (ICI) for advanced melanoma, a small group of patients with an excellent and durable response has emerged. Complete response (CR) is achievable in about 10-20% of the patients and
Autor:
C. Libenciuc, Séverine Roy, C. Robert, Emilie Routier, Y. Ech-Chennoufi, Djaouida Belkadi, François Aubin
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 146:A303-A304
Introduction Le methotrexate est un des traitements les plus couramment utilises dans la prise en charge du psoriasis etendu. La survenue d’une progression chez des patients atteints de melanome sous immunotherapie, en remission complete ou partiel